Key Points
- Insider sale: Southpoint Capital Advisors LP sold 1,000,000 Fennec Pharmaceuticals shares on Dec. 24 at an average price of C$10.35 for C$10.35M, cutting its stake by 26.7% to 2,744,741 shares (≈C$28.41M); it also sold 160,100 shares on Nov. 14 and 85,918 shares on Nov. 17.
- Stock snapshot: FRX opened at C$10.46 with a 50‑day/200‑day moving average of C$10.75/C$11.56, a market cap of C$357.24M, a 1‑year range of C$7.02–C$13.83, a negative P/E (‑40.23) and a beta of 2.78.
Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) insider Southpoint Capital Advisors Lp sold 1,000,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of C$10.35, for a total transaction of C$10,350,000.00. Following the sale, the insider owned 2,744,741 shares of the company's stock, valued at approximately C$28,408,069.35. The trade was a 26.70% decrease in their ownership of the stock.
Southpoint Capital Advisors Lp also recently made the following trade(s):
- On Friday, November 14th, Southpoint Capital Advisors Lp sold 160,100 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$11.24, for a total value of C$1,799,524.00.
- On Monday, November 17th, Southpoint Capital Advisors Lp sold 85,918 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$12.35, for a total value of C$1,061,087.30.
Fennec Pharmaceuticals Stock Performance
Shares of FRX stock opened at C$10.46 on Friday. The stock has a fifty day moving average price of C$10.75 and a 200 day moving average price of C$11.56. The company has a debt-to-equity ratio of -620.83, a quick ratio of 10.17 and a current ratio of 7.80. The stock has a market cap of C$357.24 million, a PE ratio of -40.23 and a beta of 2.78. Fennec Pharmaceuticals Inc. has a 1 year low of C$7.02 and a 1 year high of C$13.83.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
